BOK Financial Private Wealth Inc. Has $368,000 Holdings in Pfizer Inc. (NYSE:PFE)

BOK Financial Private Wealth Inc. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,866 shares of the biopharmaceutical company’s stock after selling 706 shares during the quarter. BOK Financial Private Wealth Inc.’s holdings in Pfizer were worth $368,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the 4th quarter valued at about $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer in the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the 4th quarter valued at about $28,000. Gladius Capital Management LP increased its position in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares in the last quarter. Finally, Noble Wealth Management PBC acquired a new stake in Pfizer in the 4th quarter valued at about $31,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 1.8 %

Shares of NYSE PFE opened at $26.71 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The firm has a 50 day moving average price of $26.30 and a 200 day moving average price of $27.23. The stock has a market cap of $151.35 billion, a P/E ratio of 18.94, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The business’s revenue was up 24.7% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 7th. Shareholders of record on Friday, January 24th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.44%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is presently 121.99%.

Analyst Ratings Changes

Several equities research analysts have recently commented on PFE shares. Wolfe Research started coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Guggenheim reiterated a “buy” rating and set a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Citigroup lowered their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, UBS Group lowered their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.